It also includes angiotensin II receptor blockers (ARBs), beta receptor antagonists, Sali corticosteroid receptor antagonists, and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and is a therapy based on an in-depth study of the pathophysiologic mechanisms of heart failure. This evidence concerns the gene SLC5A2 and heart failure.